News

Cupron® Performance Additives Unveils Groundbreaking “Clear” Liquid Copper Platform for Sustainable Microbial Control Applications

Cupron Performance Additives (Cupron) today announced the launch of Cupron Clear™ — a revolutionary new liquid microbial copper platform. Cupron Clear™ is a transparent, stable, and highly efficacious liquid form of copper, designed for broad use across polymers and liquids. This new breakthrough delivers unmatched microbial control while exceeding modern standards for sustainability, economics, and safety.

Cupron Clear™ reinvents the chemistry of copper-based additives for liquid products, delivering over a hundred times the effectiveness of conventional copper solutions. With its innovative clear liquid format, Cupron Clear™ out-performs incumbent additives such as QUATs and Isothiazolinones, many of which are facing growing regulatory pressure. Cupron Clear™ sets a new standard for broad-spectrum efficacy against microorganisms. This next-generation technology provides end market and downstream users with a more sustainable, versatile, and high-performing copper-based biocide than ever before.

“This new liquid copper platform addresses the frustrations for so many different industries and dramatically expands the applications that can enjoy the benefits of Cupron innovations,” said Chris Andrews, CEO of Cupron. “It’s the direct result of focused R&D and our belief that economic, safer, sustainable technologies should replace legacy materials that no longer meet regulatory or performance standards.”

Representing a major leap forward in copper-based technologies, Cupron Clear™ is a first-to-market solution for personal care, hygiene, building & construction, textiles, plastics, paints and other coatings, adhesives, sealants, elastomers (C.A.S.E.) markets in need of the highest-performing form of cuprous copper in a colorless, liquid format.

“With the addition of Cupron Clear™ to the company’s product portfolio, we can now offer our partners unparalleled flexibility in manufacturing and application with a comprehensive suite of platforms across solid, dispersion and solution-based applications,” Andrews added.

In addition to securing patents and intellectual property rights across composition, process, and applications of Cupron Clear™, Cupron is already in discussion with global partners and distributors to deploy it across core markets.

Read more here.

Recent News

03/19/2026

GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C

GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced a new genetic testing program with Zevra Therapeutics, Inc. (Nasdaq: ZVRA), a commercial-stage biopharmaceutical company focused on bringing life-changing therapeutics to people living with rare diseases. The Niemann-Pick Disease type C (NPC) Sponsored Genetic Testing

03/18/2026

Phlow Corp. Appoints Dawn Von Rohr as Chief Operating Officer to Advance Domestic Pharmaceutical Manufacturing

Phlow Corp., a leading American advanced pharmaceutical contract development and manufacturing organization (CDMO), today announced that Dawn Von Rohr has been appointed Chief Operating Officer (COO). Von Rohr will oversee Phlow’s operations, manufacturing execution, and strategic growth initiatives as the company continues expanding its advanced pharmaceutical development and manufacturing infrastructure in the United States to

03/17/2026

W&M Undergrads expand the chemical toolbox for cancer drugs

Thanks to modern therapies, a cancer diagnosis is no longer an automatic death sentence. But many patients still suffer from unwanted side effects and limited efficacy. In a recent Bioconjugate Chemistry publication, William & Mary researchers designed an antibody-drug conjugate (ADC) with the potential to improve the potency and decrease the cost of currently approved cancer drugs. Like